RLS
MCID: RST001
MIFTS: 54

Restless Legs Syndrome (RLS)

Categories: Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Restless Legs Syndrome

MalaCards integrated aliases for Restless Legs Syndrome:

Name: Restless Legs Syndrome 12 75 53 25 54 37 55 44 15 63 17 72
Restless Leg Syndrome 53 25
Willis-Ekbom Disease 12 25
Wed 12 25
Wittmaack-Ekbom Syndrome 12
Willis Ekbom Disease 53
Ekbom's Syndrome 25
Ekbom Syndrome 25
Restless Legs 43
Rls 25

Classifications:



External Ids:

Disease Ontology 12 DOID:0050425
KEGG 37 H01597
ICD9CM 35 333.94
MeSH 44 D012148
NCIt 50 C84501
SNOMED-CT 68 32914008
ICD10 33 G25.81
UMLS 72 C0035258

Summaries for Restless Legs Syndrome

Genetics Home Reference : 25 Restless legs syndrome is a neurological condition that causes an irresistible urge to move the legs. The movement is triggered by strange or uncomfortable feelings, often described as crawling, pulling, or itching, deep within both legs. The feelings usually occur while the affected person is sitting or lying down and are worse at night. Movement, such as kicking, stretching, rubbing, or pacing, make the discomfort go away, at least temporarily. The unpleasant feelings and the resulting need to move the legs often make it difficult for an affected person to fall asleep or stay asleep. The signs and symptoms of restless legs syndrome range from mild to severe; people with mild cases may experience symptoms a few times a month, while those with more severe cases may have symptoms every night. In severe cases, the uncomfortable feelings can affect the arms or other parts of the body in addition to the legs. Many people with restless legs syndrome also experience uncontrollable, repetitive leg movements that occur while they are sleeping or while relaxed or drowsy. When these movements occur during sleep, they are called periodic limb movements of sleep (PLMS); when they occur while a person is awake, they are called periodic limb movements of wakefulness (PLMW). It is unclear whether PLMS and PLMW are features of restless legs syndrome itself or represent similar, but separate, conditions. Restless legs syndrome and PLMS can affect the quality and amount of sleep. As a result of these conditions, affected individuals may have difficulty concentrating during the day, and some develop mood swings, depression, or other health problems. Researchers have described early-onset and late-onset forms of restless legs syndrome. The early-onset form begins before age 45, and sometimes as early as childhood. The signs and symptoms of this form usually worsen slowly with time. The late-onset form begins after age 45, and its signs and symptoms tend to worsen more rapidly.

MalaCards based summary : Restless Legs Syndrome, also known as restless leg syndrome, is related to restless legs syndrome 7 and restless legs syndrome 6, and has symptoms including seizures, tremor and back pain. An important gene associated with Restless Legs Syndrome is RLS1 (Restless Legs Syndrome, Susceptibility To), and among its related pathways/superpathways are Circadian rythm related genes and Monoamine GPCRs. The drugs Parathyroid hormone and Apomorphine have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and kidney.

Disease Ontology : 12 A central nervous system disease characterized by throbbing, pulling creeping or other unpleasant sensations in the legs and the irresistible urge to move them.

NIH Rare Diseases : 53 Restless legs syndrome (RLS) is a neurological condition that causes an irresistible urge to move the legs. The movement is triggered by strange or uncomfortable feelings, which occur mostly while the affected person is sitting or lying down and are worse at night. Movement (i.e. kicking, stretching, rubbing, or pacing) makes the discomfort go away, at least temporarily. Many people with restless legs syndrome also have uncontrollable, repetitive leg movements that occur while they are sleeping or while relaxed or drowsy. Researchers have described early-onset and late-onset forms of restless legs syndrome. The early-onset form begins before age 45 and progresses slowly. The late-onset form begins after age 45, and its signs and symptoms tend to worsen more rapidly. RLS likely results from a combination of genetic and environmental factors, many of which are unknown. The syndrome may also be classified in several types (RLS1, RLS2, RLS3, RLS4, RLS5, RLS6, RLS7) according to the location in specific chromosomes of some of the genes that are associated with an increased risk (susceptibility) to have the syndrome. Treatment is based on the signs and symptoms present in each person.

MedlinePlus : 43 Restless legs syndrome (RLS) causes a powerful urge to move your legs. Your legs become uncomfortable when you are lying down or sitting. Some people describe it as a creeping, crawling, tingling, or burning sensation. Moving makes your legs feel better, but not for long. RLS can make it hard to fall asleep and stay asleep. In most cases, there is no known cause for RLS. In other cases, RLS is caused by a disease or condition, such as anemia or pregnancy. Some medicines can also cause temporary RLS. Caffeine, tobacco, and alcohol may make symptoms worse. Lifestyle changes, such as regular sleep habits, relaxation techniques, and moderate exercise during the day can help. If those don't work, medicines may reduce the symptoms of RLS. Most people with RLS also have a condition called periodic limb movement disorder (PLMD). PLMD is a condition in which a person's legs twitch or jerk uncontrollably, usually during sleep. PLMD and RLS can also affect the arms. NIH: National Heart, Lung, and Blood Institute

NINDS : 54 Restless legs syndrome (RLS) is characterized by unpleasant sensations in the legs and an irresistible urge to move them. Individuals affected with the disorder often describe the sensations as throbbing, pulling, or creeping. The sensations range in severity from uncomfortable to irritating to painful. Symptoms commonly occur in late afternoon or evening and are most severe at night, when the person is resting. Moving the legs or walking typically relieves the discomfort but the symptoms often recur. RLS is both a sleep and a neurological sensory disorder.

KEGG : 37
The restless legs syndrome (RLS), also known as Willis Ekbom disease is a neurologic disorder characterized by unpleasant sensations in the legs accompanied by an urge to move them (akathisia). These symptoms occur predominantly at rest and worsen at night, resulting in nocturnal insomnia and chronic sleep deprivation. The prevalence of RLS increases with age and appears to be higher among women than among men. RLS has a high familial aggregation. To date, several loci and genetic risk factors have been identified, but no causative gene mutation has been found. Standard medications for RLS are dopamine agonists and CACN alpha-2 delta blocker. A high prevalence of iron deficiency has been found among patients with RLS. It has been reported that treatment with oral iron supplements resulted in improvements in the severity of the symptoms in patients with a low serum ferritin level.

PubMed Health : 63 About restless legs syndrome: Restless legs syndrome (RLS) is a disorder that causes a strong urge to move your legs. This urge to move often occurs with strange and unpleasant feelings in your legs. Moving your legs relieves the urge and the unpleasant feelings. People who have RLS describe the unpleasant feelings as creeping, crawling, pulling, itching, tingling, burning, aching, or electric shocks. Sometimes, these feelings also occur in the arms. The urge to move and unpleasant feelings happen when you're resting and inactive. Thus, they tend to be worse in the evening and at night.

Wikipedia : 75 Restless legs syndrome (RLS) is generally a long term disorder that causes a strong urge to move one's... more...

Related Diseases for Restless Legs Syndrome

Diseases in the Restless Legs Syndrome family:

Restless Legs Syndrome 1 Restless Legs Syndrome 2
Restless Legs Syndrome 3 Restless Legs Syndrome 4
Restless Legs Syndrome 6 Restless Legs Syndrome 5
Restless Legs Syndrome 7 Restless Legs Syndrome 8

Diseases related to Restless Legs Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 435)
# Related Disease Score Top Affiliating Genes
1 restless legs syndrome 7 35.5 RLS7 MEIS1
2 restless legs syndrome 6 35.5 RLS6 BTBD9
3 migraine with or without aura 1 31.8 HCRT DRD3 DRD2
4 pathological gambling 31.4 DRD3 DRD2 DRD1
5 parkinson disease, late-onset 31.2 HCRT DRD3 DRD2 DRD1
6 delusional disorder 30.9 DRD3 DRD2
7 impulse control disorder 30.7 DRD3 DRD2
8 obsessive-compulsive disorder 30.6 DRD3 DRD2 DRD1
9 restless legs syndrome 2 12.9
10 restless legs syndrome 1 12.9
11 restless legs syndrome 3 12.9
12 restless legs syndrome 4 12.9
13 restless legs syndrome 5 12.9
14 restless legs syndrome 8 12.8
15 sleep disorder 11.8
16 machado-joseph disease 11.7
17 periodic limb movement disorder 11.7
18 fibromyalgia 11.6
19 roussy-levy hereditary areflexic dystasia 11.4
20 persistent genital arousal disorder 11.2
21 iron metabolism disease 11.1
22 end stage renal failure 10.9
23 neuropathy 10.8
24 sleep apnea 10.8
25 polyneuropathy 10.8
26 attention deficit-hyperactivity disorder 10.8
27 peripheral nervous system disease 10.7
28 movement disease 10.7
29 uremia 10.7
30 polysubstance abuse 10.7 DRD3 DRD2
31 multiple sclerosis 10.6
32 deficiency anemia 10.6
33 tremor 10.6
34 iron deficiency anemia 10.6
35 kidney disease 10.6
36 early-onset schizophrenia 10.6 DRD2 DRD1
37 myoclonus 10.6
38 paresthesia 10.6
39 depression 10.6
40 chronic pain 10.6
41 cerebrovascular disease 10.5
42 headache 10.5
43 narcolepsy 10.5
44 anxiety 10.5
45 mental depression 10.5
46 disease of mental health 10.5 HCRT DRD3 DRD2
47 essential tremor 10.5
48 chronic kidney disease 10.5
49 erythermalgia, primary 10.5
50 ataxia and polyneuropathy, adult-onset 10.5

Graphical network of the top 20 diseases related to Restless Legs Syndrome:



Diseases related to Restless Legs Syndrome

Symptoms & Phenotypes for Restless Legs Syndrome

UMLS symptoms related to Restless Legs Syndrome:


seizures, tremor, back pain, pain, headache, syncope, excessive daytime somnolence, chronic pain, snoring, sciatica, sleep disturbances, vertigo/dizziness, sleeplessness

Drugs & Therapeutics for Restless Legs Syndrome

PubMed Health treatment related to Restless Legs Syndrome: 63

Restless legs syndrome (RLS) has no cure. If a condition or medicine triggers RLS, it may go away or get better if the trigger is relieved or stopped. RLS can be treated. The goals of treatment are to: Prevent or relieve symptomsIncrease the amount of sleep you're getting and improve the quality of your sleepTreat or correct any underlying condition that may trigger or worsen RLS Mild cases of RLS often are treated with lifestyle changes and sometimes with periodic use of medicines. More severe RLS usually is treated with daily medicines.

Drugs for Restless Legs Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 185)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
2
Apomorphine Approved, Investigational Phase 4 41372-20-7, 58-00-4 6005
3
Trimetazidine Approved, Investigational Phase 4 5011-34-7
4
Acetaminophen Approved Phase 4 103-90-2 1983
5
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
6
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
7
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
8
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
9
Levetiracetam Approved, Investigational Phase 4 102767-28-2 441341
10
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
11
Topiramate Approved Phase 4 97240-79-4 5284627
12
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
13
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
14
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
15
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
16
Amitriptyline Approved Phase 4 50-48-6 2160
17
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
18
Propranolol Approved, Investigational Phase 4 525-66-6 4946
19
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
20
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
21
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
22
Memantine Approved, Investigational Phase 4 19982-08-2 4054
23
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
24
Rizatriptan Approved Phase 4 144034-80-0, 145202-66-0 5078
25
Donepezil Approved Phase 4 120014-06-4 3152
26
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
27
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 441240 60857
28
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
29
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
30 Tocotrienol Investigational Phase 4 6829-55-6
31
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
32 Emetics Phase 4
33 Vasodilator Agents Phase 4
34 Sympathomimetics Phase 4
35 Cardiotonic Agents Phase 4
36 Autonomic Agents Phase 4
37 Antidepressive Agents Phase 4
38 Neurotransmitter Uptake Inhibitors Phase 4
39 Serotonin Receptor Agonists Phase 4
40 Serotonin Agents Phase 4
41 Hypoglycemic Agents Phase 4
42 Cyclooxygenase Inhibitors Phase 4
43 diuretics Phase 4
44 Cyclooxygenase 2 Inhibitors Phase 4
45 Sodium Potassium Chloride Symporter Inhibitors Phase 4
46 Natriuretic Agents Phase 4
47 Anti-Inflammatory Agents, Non-Steroidal Phase 4
48 Anti-Inflammatory Agents Phase 4
49 Antirheumatic Agents Phase 4
50 Serotonin Uptake Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 237)
# Name Status NCT ID Phase Drugs
1 Evaluation of Cholecalciferol Supplementation in Chronic Kidney Disease Patients With Restless Leg Syndrome Unknown status NCT03063190 Phase 4 Vitamin D;Placebo Oral Tablet
2 Effects of Gabapentin Enacarbil on Intensity of Cortical Arousal, Heart Rate, Blood Pressure and Anterior Tibialis EMG Responses Associated With PLMs During Sleep in Patients With RLS Using a Novel Computer Assisted Scoring System Unknown status NCT02424695 Phase 4 Gabapentin Enacarbil (GEn);Placebo
3 Double Bind Randomized Placebo-controlled Cross-over Study to Evaluate Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease Unknown status NCT02940912 Phase 4 Apomorphine;Placebo
4 The Study to Assess the Effect of Trimetazidine on Index of Microcirculatory Resistance (IMR), Measured by Coronary Pressure and Temperature Wire, in Patients With Stable Coronary Artery Disease Unknown status NCT02107144 Phase 4 trimetazidine
5 A Method to Switch From Oral Dopamine Agonists to Rotigotine in Patients With Restless Legs Syndrome Completed NCT01976871 Phase 4 Rotigotine
6 Exploratory Study of the Efficacy, Practicability and Safety of Intravenous Iron Supplementation Therapy in Moderate to Severe Restless Legs Syndrome With Iron Deficiency or Anaemia in the 3rd Trimester of Pregnancy Completed NCT01245777 Phase 4 ferric carboxymaltose
7 Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome: AUTOREST, a Case-control Study and a Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week, Multicenter Study of 0.25mg Pramipexole vs. Placebo in Patients With RLS Completed NCT02025608 Phase 4 Pramipexole;Placebo
8 A 12-Week, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Flexible Dose Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome (RLS) in RLS Patients With Sleep Disturbance and Periodic Limb Movements (PLM) During Sleep Completed NCT00373542 Phase 4 ropinirole CR-RLS
9 Gabapentin Enacarbil Post-marketing Clinical Study A Randomized, Double-blind, Placebo-controlled, Parallel-group Study in Subjects With Restless Legs Syndrome. Completed NCT03053427 Phase 4 Placebo;Gabapentin enacarbil
10 A Parallel Group Study to Evaluate the Efficacy and Safety of Ropinirole for 26 Weeks and to Further Evaluate the Incidence of Augmentation and Rebound for a Further 40 Weeks Open-label Extension Treatment Period in Subjects Suffering From Moderate to Severe Restless Legs Syndrome. Completed NCT00329602 Phase 4 Placebo;Ropinirole
11 A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With Pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/Day Per os for 12 Weeks to Investigate the Effects on RLS Symptoms (IRLS) and Sleep Disturbance (MOS Sleep Scale) in Out-patients With Idiopathic Restless Legs Syndrome Completed NCT00349531 Phase 4 Pramipexole
12 A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With 0.125-0.75 mg/Day Pramipexole (Sifrol®, Mirapexin®) Orally for 12 Weeks to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome Associated With Mood Disturbances Completed NCT00356096 Phase 4 pramipexole
13 Post-marketing Clinical Study of Gabapentin Enacarbil ―Non-blinded Study in Restless Legs Syndrome (RLS) Patients With Moderate Renal Impairment― Completed NCT01981941 Phase 4 Gabapentin enacarbil
14 A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With Pramipexole (Sifrol, Mirapexin) 0.125-0.75 mg/Day Per os to Investigate the Long-term Efficacy, Safety and Tolerability in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome for 26 Weeks Followed by a 26 Week Open-label Extension Treatment Period Completed NCT00472199 Phase 4 Pramipexole;Placebo
15 Multicenter, Double-Blind, Placebo-Controlled, Two-Arm, Randomized, Parallel, Treatment Intervention, Sleep Lab Phase 4 Study to Assess the Effect of Rotigotine on Nocturnal Blood Pressure in Patients With Idiopathic Restless Legs Syndrome Completed NCT01455012 Phase 4 Rotigotine;Placebo
16 A Phase IV Randomised, Double-blind, Active and Placebo-controlled, 6-week Trial to Investigate the Efficacy and Safety of a Starting (and Fixed) Dose 0.25 mg Pramipexole (Mirapex®) in Patients With Idiopathic Restless Legs Syndrome Completed NCT00375284 Phase 4 Pramipexole
17 Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome : a Pilot Randomized, Placebo-controlled Study Completed NCT01823770 Phase 4 Rotigotine;Placebo patchs
18 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Effacy and Safety of Topiramate in Subjects With Restless Legs Syndrome (RLS) Completed NCT00200941 Phase 4 Topiramate
19 A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group Study to Compare the Efficacy, Tolerability, and Safety of 3 Doses of Gabapentin Enacarbil (GSK1838262) With Placebo in the Treatment of Subjects With Moderate-to-Severe Primary Restless Legs Syndrome (RLS) Completed NCT01668667 Phase 4 GSK1838262 600 mg;GSK1838262 450 mg;GSK1838262 300 mg;GSK1838262 Placebo match
20 A Prospective, Randomized Study Evaluating the Efficacy and Safety of Early Diuresis Following Colorectal Surgery Completed NCT02351934 Phase 4 Furosemide;Celecoxib;Gabapentin
21 An Open-Label Prospective Study of Restless Legs Patients Switched to Ropinirole From Pramipexole to Help Determine the Equipotent Dose Completed NCT00344994 Phase 4 pramipexole
22 Treatment of Sexual Dysfunction Secondary to Antidepressant Pharmacotherapy: A Double-blind Comparison of Requip (Ropinirole) vs. Placebo in Patients Taking SSRI Antidepressants Completed NCT00334048 Phase 4 Ropinirole (Requip)
23 A Multicenter, Double-Blind, Placebo Controlled, Parallel Group, Efficacy and Safety Evaluation of HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) in Adolescents Aged 13 to 17 Years Old With Moderate-to-Severe Primary RLS Recruiting NCT02560766 Phase 4 HORIZANT 300 mg;HORIZANT 600 mg;Placebo
24 A Multicenter Open-Label Extension Study to Evaluate the Efficacy and Safety of HORIZANT (Gabapentin Enacarbil) Extended-Release Tablets in Adolescents Aged 13 to 17 Years Old With Moderate-to-Severe Primary Restless Legs Syndrome Recruiting NCT02633683 Phase 4 HORIZANT 600 mg
25 Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease Recruiting NCT03082755 Phase 4 Gabapentin Enacarbil;Placebo Oral Tablet
26 Gabapentin as an Adjunct for Pain Management During Dilation and Evacuation: A Double-blind Randomized Controlled Trial Recruiting NCT03635905 Phase 4 Gabapentin;Placebo
27 Quality Improvement and Practice Based Research in Neurology Using the Electronic Medical Record Enrolling by invitation NCT02670161 Phase 4 Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
28 Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis Enrolling by invitation NCT03176966 Phase 4 Vitamin E;Ropinirole
29 A Randomized Controlled Trial of Pramipexole for Restless Leg Syndrome in Peritoneal Dialysis Patients Not yet recruiting NCT03817554 Phase 4 Pramipexole
30 Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome Terminated NCT02117076 Phase 4 Gabapentin immediate release;Gabapentin enacarbil extended release
31 The Effect of Gabapentin on Postoperative Pain: a Randomized, Double Blind, Placebo Controlled Trial Terminated NCT01546857 Phase 4 Placebo;Gapabentin
32 Butrans for Treatment of Restless Legs Syndrome Withdrawn NCT02138357 Phase 4 buprenorphine transdermal delivery system (BTDS);Placebo for BTDS patch
33 Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome Withdrawn NCT00584246 Phase 4 Pregabalin (Lyrica);Placebo
34 A Randomised Clinical Trial Comparing Standard Cannula Delivered Foam Sclerotherapy, Catheter Directed Foam Sclerotherapy and ClariVein® Mechanochemical Ablation in the Management of Superficial Venous Insufficiency. Withdrawn NCT02010437 Phase 4 Sodium Tetradecyl Sulphate (STS)
35 Vitamin D in the Treatment of Primary Restless Legs Syndrome: 12 Weeks, Triple-blinded, Randomized, Placebo-controlled Trial Unknown status NCT02256215 Phase 2, Phase 3 Vitamin D
36 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Five-Arm Parallel-Group Trial to Investigate the Efficacy and Safety of Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome Completed NCT00135993 Phase 3 Rotigotine
37 A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole XR (Extended Release) in Patients With Restless Legs Syndrome Completed NCT00197080 Phase 3 Ropinirole Extended Release (XR)
38 A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS) Completed NCT00314860 Phase 3 ropinirole Extended Release (XR)
39 Long-term Study - Long-term Efficacy and Safety of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients Completed NCT02658188 Phase 3 ASP8825
40 A Randomized, Double-blind, Placebo Controlled Dose Titration Trial With 0.125-0.75 mg Pramipexole (Sifrol®) Orally q.n. to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome for 6 Weeks Completed NCT00654498 Phase 3 Pramipexole;Placebo
41 A 12-week, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Intermittent Dosing of Ropinirole in Patients With Restless Legs Syndrome (RLS) Completed NCT00225862 Phase 3 ropinirole
42 A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome. Completed NCT00298623 Phase 3 XP13512 (GSK1838262)
43 A Randomized, Double-Blind, Placebo-Controlled, 3-Way Crossover, Multicenter Polysomnography Study Of Pregabalin And Pramipexole In Adults With Restless Legs Syndrome Completed NCT00991276 Phase 3 pregabalin;placebo;pramipexole
44 A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering From Restless Legs Syndrome (RLS) Completed NCT00363857 Phase 3 Ropinirole
45 A Multi-center, Randomized, Double-blind, Placebo-controlled, Four-arm Parallel-group Trial to Investigate the Efficacy and Safety of Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome Completed NCT00136045 Phase 3 Rotigotine
46 A Multi-center, Double-blind, Randomized, Placebo-controlled, Two-arm, Parallel-group, Sleep Lab Trial to Investigate the Efficacy and Safety of Transdermal Rotigotine in Subjects With Idiopathic Restless Legs Syndrome Completed NCT00275236 Phase 3 Rotigotine
47 A 52-Week, Open-Label Study to Assess the Long-Term Safety of Ropinirole Extended Release (XR) in Patients With Restless Legs Syndrome (RLS) Completed NCT00355641 Phase 3 Ropinirole Extended Release (XR)
48 A Randomized, Double-blind, Placebo-controlled, Parallel Group Clinical Trial Comparing Fixed Doses of 0.25 mg, 0.50 mg and 0.75 mg Pramipexole (Mirapex®) Administered Orally to Investigate the Safety and Efficacy in Patients With Idiopathic Restless Legs Syndrome for 12 Weeks Completed NCT00133198 Phase 3 Pramipexole
49 An Open-Label, 52-Week Extension Study Assessing XP13512 Safety and Efficacy in Patients With Restless Legs Syndrome. Completed NCT00333359 Phase 3 XP13512 (GEn)
50 An Open-label Extension Trial to Investigate the Safety and Tolerability of Long-term Treatment With Transdermal Rotigotine in Subjects With Idiopathic Restless Legs Syndrome Completed NCT00498108 Phase 3 Rotigotine

Search NIH Clinical Center for Restless Legs Syndrome

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Amantadine
Carbamazepine
Carbamazepine
Clonazepam
Clonazepam
Gabapentin
Gabapentin enacarbil
Iron
Levodopa

Cochrane evidence based reviews: restless legs syndrome

Genetic Tests for Restless Legs Syndrome

Anatomical Context for Restless Legs Syndrome

MalaCards organs/tissues related to Restless Legs Syndrome:

41
Brain, Heart, Kidney, Testes, Spinal Cord, Lung, Liver

Publications for Restless Legs Syndrome

Articles related to Restless Legs Syndrome:

(show top 50) (show all 3725)
# Title Authors PMID Year
1
Restless legs syndrome and quality of life in pregnant women. 38 17
31166437 2019
2
Paeoniae Radix-containing herbal medicine for patients with restless legs syndrome: A systematic review and meta-analysis. 38 17
31003678 2019
3
Restless legs syndrome in end stage renal disease patients undergoing hemodialysis. 38 17
30925907 2019
4
Circadian variation of hypocretin-1 (orexin A) in restless legs syndrome. 9 38
19013101 2009
5
Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease. 9 38
18207455 2009
6
Spinocerebellar ataxia type 1, 2, and 3 and restless legs syndrome: striatal dopamine D2 receptor status investigated by [11C]raclopride positron emission tomography. 9 38
16941469 2006
7
Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. 9 38
16816393 2006
8
Ferritin levels in the cerebrospinal fluid and restless legs syndrome: effects of different clinical phenotypes. 9 38
16268375 2005
9
CSF iron, ferritin and transferrin levels in restless legs syndrome. 9 38
15743333 2005
10
Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. 9 38
15136682 2004
11
Iron metabolism and the risk of restless legs syndrome in an elderly general population--the MEMO-Study. 9 38
12242538 2002
12
Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome. 9 38
12196669 2002
13
Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. 9 38
10762522 2000
14
Decreased serum ferritin may be associated with increased restless legs syndrome in Parkinson's disease (PD): a meta-analysis for the diagnosis of RLS in PD patients. 38
31092087 2019
15
Sleep disorders in patients with psoriasis: a cross-sectional study using non-polysomnographical methods. 38
30859369 2019
16
Sleep, Sleep Disorders, and Sexual Dysfunction. 38
30209897 2019
17
Restless legs syndrome effectively treated with constant-pressure predilution online hemodiafiltration. 38
30919160 2019
18
Restless legs syndrome, periodic limb movements during sleep and cardiovascular risk. 38
31331694 2019
19
Corrigendum to "Short-term effects of massage with olive oil on the severity of uremic restless legs syndrome: A double-blind placebo-controlled trial" [Complement Ther Med 44 (June) (2019) 261-268]. 38
31331578 2019
20
The Epidemiology of Patient-Reported Hypersomnia in Persons With Advanced Age. 38
31390046 2019
21
REM sleep without atonia constitutes increased risk for neurodegenerative disorders. 38
31411727 2019
22
Leg restlessness preceding the onset of motor symptoms of Parkinson disease: A case series of 5 patients. 38
31415433 2019
23
The Relationship between Restless Legs Syndrome and Quality of Life in Patients with Myasthenia Gravis. 38
31390624 2019
24
Restless Legs Syndrome Related to Vortioxetine: A Case Report. 38
31433340 2019
25
Advancing synthetic therapies for the treatment of restless legs syndrome. 38
31424287 2019
26
Genome-wide association analysis of self-reported daytime sleepiness identifies 42 loci that suggest biological subtypes. 38
31409809 2019
27
Corrigendum to "Restless legs syndrome in NKX2-1-related chorea: An expansion of the disease spectrum" [Brain Dev. 41 (2019) 250-256]. 38
31053344 2019
28
Screening questions for the diagnosis of restless legs syndrome in hemodialysis. 38
31384449 2019
29
Impaired endothelial function may predict treatment response in restless legs syndrome. 38
31218470 2019
30
Spinal Cord Stimulation in Patients With Chronic Pain and Restless Legs Syndrome: A Case Report. 38
30933049 2019
31
Restless legs syndrome is associated with arterial stiffness and clinical outcome in stroke patients. 38
31186216 2019
32
Non-pharmacological interventions for restless legs syndrome: a systematic review of randomised controlled trials. 38
29561180 2019
33
The experience of living with restless legs syndrome: A qualitative study. 38
31434518 2019
34
The impact of rotating work schedules, chronotype, and restless legs syndrome/Willis-Ekbom disease on sleep quality among female hospital nurses and midwives: A cross-sectional survey. 38
31129552 2019
35
Association between predialysis hypermagnesaemia and morbidity of uraemic restless legs syndrome in maintenance haemodialysis patients: a retrospective observational study in Zhejiang, China. 38
31292178 2019
36
Comparison of sleep complaints and quality of life between patients with neuromyelitis optica spectrum disorder (NMOSD) and healthy controls. 38
31063950 2019
37
Postpolio Syndrome: A Review of Lived Experiences of Patients. 38
31392174 2019
38
Sleep Disorders in Hereditary Ataxias. 38
31342187 2019
39
The role of exercise in improving patient-reported outcomes in individuals on dialysis: A scoping review. 38
31006928 2019
40
Painful Willis-Ekbom disease: unbearable and distinct form of restless legs? 38
31256071 2019
41
Hyperactivity, dopaminergic abnormalities, iron deficiency and anemia in an in vivo opioid receptors knockout mouse: Implications for the restless legs syndrome. 38
31376441 2019
42
Drug Treatment of Restless Legs Syndrome in Older Adults. 38
31347095 2019
43
The Comorbidity of Migraine and Restless Legs Syndrome. 38
31352574 2019
44
Restless Legs Syndrome in Parkinson's Disease Patients: Clinical Features Including Motor and Nonmotor Symptoms. 38
31286703 2019
45
Peculiar lifespan changes of periodic leg movements during sleep in restless legs syndrome. 38
31313413 2019
46
Clinical features and subtypes of restless legs syndrome in Chinese population: a study of 359 patients. 38
31153012 2019
47
Extracellular vesicles reveal abnormalities in neuronal iron metabolism in restless legs syndrome. 38
30895312 2019
48
Characterization of painful Restless Legs Syndrome sensations in an English-speaking South African population. 38
30796850 2019
49
Evaluation of potential cardiovascular risk protein biomarkers in high severity restless legs syndrome. 38
31338581 2019
50
Creativity related to dopaminergic treatment: A multicenter study. 38
30824283 2019

Variations for Restless Legs Syndrome

Expression for Restless Legs Syndrome

Search GEO for disease gene expression data for Restless Legs Syndrome.

Pathways for Restless Legs Syndrome

Pathways related to Restless Legs Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
2
Show member pathways
11.47 DRD3 DRD2 DRD1
3 11.28 MAP2K5 DRD2 DRD1
4 10.14 DRD3 DRD2 DRD1

GO Terms for Restless Legs Syndrome

Cellular components related to Restless Legs Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 glutamatergic synapse GO:0098978 9.46 PTPRD DRD3 DRD2 DRD1
2 dopaminergic synapse GO:0098691 8.96 DRD3 DRD2
3 GABA-ergic synapse GO:0098982 8.8 DRD3 DRD2 DRD1

Biological processes related to Restless Legs Syndrome according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 visual learning GO:0008542 9.73 DRD3 DRD2 DRD1
2 locomotory behavior GO:0007626 9.73 MEIS1 DRD3 DRD2 DRD1
3 response to cocaine GO:0042220 9.71 DRD3 DRD2 DRD1
4 response to morphine GO:0043278 9.65 DRD3 DRD2
5 associative learning GO:0008306 9.65 DRD2 DRD1
6 response to amphetamine GO:0001975 9.65 DRD3 DRD2 DRD1
7 negative regulation of blood pressure GO:0045776 9.64 DRD3 DRD2
8 arachidonic acid secretion GO:0050482 9.64 DRD3 DRD2
9 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.63 DRD3 DRD2
10 negative regulation of protein secretion GO:0050709 9.63 DRD3 DRD2
11 feeding behavior GO:0007631 9.63 HCRT DRD2 DRD1
12 striatum development GO:0021756 9.62 DRD2 DRD1
13 positive regulation of renal sodium excretion GO:0035815 9.62 DRD3 DRD2
14 grooming behavior GO:0007625 9.61 DRD2 DRD1
15 G protein-coupled receptor internalization GO:0002031 9.61 DRD3 DRD2
16 peristalsis GO:0030432 9.6 DRD2 DRD1
17 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.59 DRD3 DRD2
18 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.58 DRD3 DRD1
19 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.58 DRD2 DRD1
20 temperature homeostasis GO:0001659 9.58 HCRT DRD2 DRD1
21 cerebral cortex GABAergic interneuron migration GO:0021853 9.57 DRD2 DRD1
22 negative regulation of dopamine receptor signaling pathway GO:0060160 9.55 DRD3 DRD2
23 behavioral response to cocaine GO:0048148 9.54 DRD3 DRD2 DRD1
24 response to histamine GO:0034776 9.52 DRD3 DRD2
25 regulation of locomotion involved in locomotory behavior GO:0090325 9.51 DRD3 DRD2
26 synaptic transmission, dopaminergic GO:0001963 9.5 DRD3 DRD2 DRD1
27 acid secretion GO:0046717 9.49 DRD3 DRD2
28 dopamine receptor signaling pathway GO:0007212 9.43 DRD3 DRD2 DRD1
29 prepulse inhibition GO:0060134 9.33 DRD3 DRD2 DRD1
30 dopamine metabolic process GO:0042417 9.13 DRD3 DRD2 DRD1
31 regulation of dopamine uptake involved in synaptic transmission GO:0051584 8.8 DRD3 DRD2 DRD1

Molecular functions related to Restless Legs Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 adrenergic receptor activity GO:0004935 9.26 DRD3 DRD2
2 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.16 DRD3 DRD2
3 dopamine binding GO:0035240 9.13 DRD3 DRD2 DRD1
4 dopamine neurotransmitter receptor activity GO:0004952 8.8 DRD3 DRD2 DRD1

Sources for Restless Legs Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....